Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) EPS (Basic) (2021 - 2026)

Zentalis Pharmaceuticals has reported EPS (Basic) over the past 6 years, most recently at -$0.5 for Q1 2026.

  • For Q1 2026, EPS (Basic) rose 25.37% year-over-year to -$0.5; the TTM value through Mar 2026 reached -$1.73, up 44.73%, while the annual FY2025 figure was -$1.91, 18.03% up from the prior year.
  • EPS (Basic) for Q1 2026 was -$0.5 at Zentalis Pharmaceuticals, down from -$0.49 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.14 in Q1 2024 and troughed at -$1.85 in Q2 2023.
  • A 5-year average of -$0.81 and a median of -$0.79 in 2023 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): crashed 7338.06% in 2022 and later skyrocketed 113.08% in 2024.
  • Year by year, EPS (Basic) stood at -$0.92 in 2022, then rose by 9.78% to -$0.83 in 2023, then increased by 20.48% to -$0.66 in 2024, then increased by 25.76% to -$0.49 in 2025, then fell by 2.04% to -$0.5 in 2026.
  • Business Quant data shows EPS (Basic) for ZNTL at -$0.5 in Q1 2026, -$0.49 in Q4 2025, and -$0.37 in Q3 2025.